FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Zydus Petition on Indocin Suppositories

Zydus Pharmaceuticals asks FDA to ensure that Indocin suppositories and their generics meet ICH guidelines and established impurity acceptance criteri...

latest-news-card-1
Human Drugs

FDA, Rocket Agree on Phase 2 Danon Disease Trial

Rocket Pharmaceuticals says it has reached an agreement with FDA on a pivotal Phase 2 trial of an investigational gene therapy for Dannon Disease.

latest-news-card-1
Human Drugs

Safety Concerns Stop Eiger Phase 3 Hepatitis Trial

Eiger Pharmaceuticals says it is shutting down the Phase 3 LIMT-2 trial of peginterferon lambda in patients with chronic hepatitis delta for safety re...

latest-news-card-1
Human Drugs

Supremes May Hear Label Preemption Case: Attorneys

Two Knobbe Martens attorneys say the Supreme Court could clarify the bounds of federal preemption of state tort claims based on drug labels if it take...

latest-news-card-1
Biologics

Include ICH Q12 in Gene Therapy Guidance: ISPE

The International Society for Pharmaceutical Engineering says FDA should incorporate provisions in an ICH product lifecycle management guideline in an...

latest-news-card-1
Medical Devices

FDA Clears Wellysis Wearable ECG Patch

FDA clears the Samsung Wellysis units wearable electrocardiography patch, S-Patch Ex.

Human Drugs

White House Credits FDA on Drug Shortages

The White House credits FDA actions in helping to reduce cancer drug shortages.

latest-news-card-1
Medical Devices

Abbott Recalls Proclaim Pulse Generators

Abbott recalls its Proclaim and Infinity implantable pulse generators due to complaints from patients who are unable to exit MRI mode.

latest-news-card-1
Human Drugs

Madrigal NDA for Nonalcoholic Steatohepatitis

FDA accepts for priority review a Madrigal Pharmaceuticals NDA for resmetirom and its use in treating adult patients with nonalcoholic steatohepatitis...

latest-news-card-1
Federal Register

Oxandrin Withdrawn Due to Safety/Efficacy

Federal Register notice: FDA determines that Gemini Laboratories Oxandrin (oxandrolone) tablets, 2.5 mg and 10 mg, were withdrawn from sale for reason...